MICROMIRs
AssigneeRoche Innovation Center Copenhagen A/S
InventorsSusanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
Life of this patent
Estimating the term…
Abstract
The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
Claims42
An oligomer of a contiguous sequence of 7, 8, 9, or 10 nucleotide units in length, wherein at least 70% of the nucleotide units of the oligomer are selected from the group consisting of LNA (Locked Nucleic Acid) units and 2′ substituted nucleotide analogues, and wherein at least 50% of the nucleotide units of the oligomer are LNA units, and wherein at least one of the internucleoside linkages present between the nucleotide units of the contiguous nucleotide sequence is a phosphorothioate internucleoside linkage, wherein the contiguous nucleotide sequence is 100% complementary to the seed sequence of miR-155 (SEQ ID NO:
- 315), and wherein the seed sequence of miR-155 consists of nucleotides 2 to 8 of SEQ ID NO:
- 315) counting from the sequence's 5′ end.
Dependencies are inferred from the claim text.